15 results about "Capecitabine" patented technology

The application provides a cattail extract capable of preventing and treating breast cancer and an application thereof, and belongs to the technical field of biological medicine. The cattail extract is prepared by the following steps: peeling cattails, drying and crushing cattail flesh to obtain cattail flesh powder; mixing the cattail flesh powder with water to extract, filtering to obtain filtrate and residue; concentrating the filtrate to obtain a concentrate, mixing the concentrate with an ethanol solution, standing, taking the precipitate and drying to obtain dry powder 1; mixing the residue with an ethanol solution, ultrasonic extraction, taking the extract and drying to obtain dry powder 2; and mixing the dry powder 1 and the dry powder 2 to obtain the cattail extract. The cattail extract has the advantages of sufficient extraction of active ingredients, various effective components and strong overall anti-tumor effect, and can achieve an ideal effect of preventing and treating breast cancer. The cattail extract is combined with capecitabine, which can synergistically enhance the anti-breast cancer effect, reverse drug resistance, reduce toxic side effects, and greatly improve the treatment tolerance and safety.

The disclosure relates generally to compositions comprising a CDA inhibitor, e.g., tetrahydrouridine or an analog or derivative thereof, and methods for treating, reducing or inhibiting a symptom, complication or side effect, such as palmar-plantar erythrodysesthesia, caused by chemotherapy, such as 5-fluorouracil chemotherapy, especially, capecitabine chemotherapy, by administering a CDA inhibitor, e.g., tetrahydrouridine or an analog or derivative thereof. The disclosure also relates to treating cancer by co-administering capecitabine and a CDA inhibitor, e.g., tetrahydrouridine or an analog or derivative thereof to a subject.

The application discloses application of a pharmaceutical composition with GL-V9 and a chemotherapeutic drug as active ingredients in treatment of tumors, and the GL-V9 can obviously achieve a drug synergistic effect when the GL-V9 is combined with a classical chemotherapeutic drug to treat tumors, and the effect is obviously superior to combination of similar drugs and the chemotherapeutic drug. The chemotherapeutic drugs include PARP1 inhibitors, capecitabine, irinotecan, sorafenib, cisplatin or 5-fluorouracil; and the tumor types include leukemia, colorectal cancer and lung cancer.

The invention discloses a pharmaceutical composition of a pentacyclic triterpenoid and capecitabine and application of the pharmaceutical composition, and belongs to the technical field of biological medicines. By reducing the hydrolysis of capecitabine in gastrointestinal tracts and livers, the pharmaceutical composition not only slows down the early release of capecitabine drug bodies in gastrointestinal tracts and livers, increases the total bioavailability of the drug bodies and 5-fluorouracil, reduces the non-uniform high distribution of capecitabine in normal tissues such as gastrointestinal tissues, but also improves the bioavailability of capecitabine in gastrointestinal tracts and livers. Reducing toxicity in these tissues; meanwhile, the effectiveness of the medicine is improved by relatively increasing the medicine distribution of the targeted tumor part. The combination will be suitable for all tumor treatment, especially solid tumor treatment.

Methods of treating gastric cancer or gastroesophageal junction cancer in subjects are described. The methods may comprise administering an anti-FGFR2b antibody to the subject. The methods may further comprise administering a chemotherapy regimen comprising (a) oxaliplatin and capecitabine; or (b) oxaliplatin and S-1 to the subject.

The present disclosure provides, inter alia, methods of personalizing the administration of PCS6422 in combination with capecitabine, methods of personalizing cancer therapy, and methods of determining the frequency of administration of (i) PCS6422 with capecitabine or (ii) capecitabine in a subject.

The present application relates to methods of treating ocular diseases. In particular, the present application provides the use of a combination therapy of administering a thymidylate synthetase inhibitor and a vascular endothelial growth factor inhibitor and a monotherapy of administering capecitabine in ocular diseases. The diseases have one or more of the following characteristics: ocular vascular leakage, ocular vascular pathology, retinal fibrosis, scarring, and retinal inflammation. Representative diseases include neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

The invention belongs to the technical field of biological medicine, and discloses a marker for pancreatic cancer chemotherapy drug sensitivity evaluation and application thereof. According to the molecular marker for evaluating the sensitivity of the pancreatic cancer chemotherapeutic drug, the drug is a combined drug of gemcitabine and capecitabine, the molecular marker comprises a marker group 1 and a marker group 2, the marker group 1 is composed of hsa-miR-145, hsa-miR-489, hsa-miR-192, hsa-miR-221, hsa-miR-100, hsa-miR-630 and hsa-miR-141, and the marker group 2 is composed of hsa-miR-489, hsa-miR-192, hsa-miR-221, hsa-miR-100, hsa-miR-630 and hsa-miR-141. And the marker group 2 is composed of hsa-miR-760, hsa-miR-520b, hsa-miR-452, hsa-miR-18a and hsa-miR-139, and the marker group 2 is composed of hsa-miR-760, hsa-miR-520b, hsa-miR-452,

This invention provides a purification method for compound I, a key intermediate of capecitabine. The crude compound I is dissolved in an organic solvent, stirred at a first temperature, and primary tar is removed. Water is added at room temperature, and the pH is adjusted to alkaline with alkali to remove secondary tar. The organic phase is then concentrated and recrystallized. Compared to existing technologies or traditional column chromatography processes, the purification method provided by this invention significantly improves product purity, removes tar-like substances and impurities of similar polarity generated during preparation, ensuring that the content of the toxic impurity methyl methanesulfonate in the intermediate is less than 1.0 ppm, yielding a white solid compound I with a purity ≥99%. This method is suitable for large-scale industrial production, avoids column chromatography separation, is low-cost, and environmentally friendly.

The invention discloses application of carperitide in preparation of a medicine for enhancing the killing effect of MSLN-CAR-T cells on tumor cells, and finds that the carperitide can promote the MSLN-CAR-T cells to kill lung cancer cells treated by lactic acid, can up-regulate expression in MSLN brain metastatic tumor tissues and can promote the MSLN-CAR-T cells to kill lung cancer brain metastatic tumors. The invention prompts that the carperitide is expected to be combined with MSLN-CAR-T cells for medication, is used for overcoming MSLN-CAR-T cell treatment limitation caused by MSLN expression down-regulation caused by lactic acid accumulation in a lung cancer brain metastatic tumor microenvironment, and has potential clinical value.

Provided are a pharmaceutical composition for treating colorectal cancer and use thereof. Active ingredients of the pharmaceutical composition comprise: polyethylene glycol modified IL-2 and capecitabine. The pharmaceutical composition shows a very good therapeutic effect in an animal model of colorectal cancer. The effect is remarkably superior to that of a single drug, and thus the pharmaceutical composition has a good application prospect.

The disclosure relates generally to compositions comprising a CDA inhibitor, e.g., tetrahydrouridine or an analog or derivative thereof, and methods for treating, reducing or inhibiting a symptom, complication or side effect, such as palmar-plantar erythrodysesthesia, caused by chemotherapy, such as 5-fluorouracil chemotherapy, especially, capecitabine chemotherapy, by administering a CDA inhibitor, e.g., tetrahydrouridine or an analog or derivative thereof. The disclosure also relates to treating cancer by co-administering capecitabine and a CDA inhibitor, e.g., tetrahydrouridine or an analog or derivative thereof to a subject.

A mitoxantrone liposome and capecitabine are used in treating nasopharyngeal carcinoma, in particular recurrent and / or metastatic nasopharyngeal carcinoma. Nasopharyngeal carcinoma, in particular recurrent and / or metastatic nasopharyngeal carcinoma, can be treated by administering a therapeutically effective dose of the mitoxantrone liposome and capecitabine to a patient with nasopharyngeal carcinoma.

This invention discloses the application of a pharmaceutical composition with GL-V9 and chemotherapeutic drugs as active ingredients in the treatment of tumors. When GL-V9 is combined with classic chemotherapeutic drugs to treat tumors, it can achieve a significant synergistic effect, and its effect is significantly better than the combination of similar drugs and chemotherapeutic agents. These chemotherapeutic drugs include capecitabine; the tumor types include leukemia, colorectal cancer, and lung cancer.

The invention provides a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of pancreatic cancer, in particular a CCR1 antagonist, for example in combination with one or more further therapeutic agents effective as anti-tumour agents in the treatment of pancreatic cancer. Such an anti-tumour agent may be a chemotherapeutic agent selected from Gemcitabine, Fluorouracil (5-FU), Capecitabine, FOLFIRINOX (Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride and Oxaliplatin), Nab-paclitaxel (Abraxane®) and combinations thereof. An immuno-oncology agent (e.g. a PD-1 inhibitor and / or a PD-L1 inhibitor) may also favourably be used with the CCR1 antagonist.